Pdt Partners, LLC Astria Therapeutics, Inc. Transaction History
Pdt Partners, LLC
- $1.28 Billion
- Q1 2025
A detailed history of Pdt Partners, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 28,707 shares of ATXS stock, worth $168,223. This represents 0.01% of its overall portfolio holdings.
Number of Shares
28,707
Previous 10,507
173.22%
Holding current value
$168,223
Previous $92,000
66.3%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
119Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$38 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$29.9 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$24.5 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$22.4 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$20.8 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $88.9M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...